Broad Institute co-founder Stuart Schreiber is teaming up with an all-star list of scientists and financial backers to found Arena BioWorks, which Schreiber said is intended to let scientists focus on developing their hypotheses rather than seeking government grants and then later on, if their research yields something of therapeutic potential, venture capital funding.
Key Takeaways
-
Arena BioWorks will seek to fund researcher-driven science into mechanistic understanding of disease that will be allowed to develop over long timeframes.
-
A key goal is to provide a single funding source for basic and translational research, whereas scientists now often have to seek government grants first and then venture capital backing
Based in Cambridge, MA, the institute will support basic scientific research into the mechanisms of human disease and the translation of promising findings into drug candidate research and development, through biotechs launched within its own ecosystem, Schreiber, the new entity’s CEO, told Scrip
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
